Real-world look at severe respiratory failure (ARDS)
Official title: A Real World Study of Respiratory Critical Disease.
Run by Shanghai Zhongshan Hospital · NCT07165717 · Data updated 2026-11-12
This project will collect real-world data on adults at high risk for ARDS to see which clinical factors predict worse outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Shanghai Zhongshan Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | March 1, 2019 |
| Main results expected | July 31, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | September 10, 2025 |
| Trial ID | NCT07165717 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults hospitalized with conditions that put them at high risk for ARDS (such as sepsis, pneumonia, major trauma, pulmonary contusion, inhalation injury, or massive transfusion) who can provide informed consent are ideal candidates.
✕Probably not a fit
Children under 18, people with HIV or other known immunodeficiencies, transplant recipients, patients receiving G-CSF/GM-CSF, or those who have chosen to stop active treatment are excluded and unlikely to benefit from this study's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational cohort at Fudan University Zhong Shan Hospital enrolling adult patients who are at high risk for developing ARDS (for example from sepsis, pneumonia, major trauma, pulmonary contusion, inhalation injury, or massive transfusion). No experimental treatments are given; clinical data, treatments (including mechanical ventilation), and outcomes will be recorded to identify prognostic factors. Patients under 18, those with HIV, known immunodeficiency, prior organ or bone marrow transplant, those receiving G-CSF/GM-CSF, or those who have decided to withdraw active treatment are excluded. The goal is to use real-world hospital data to refine risk prediction and inform care strategies that could reduce poor outcomes in ARDS.
Why it matters
Potential benefit: If successful, the findings could help clinicians spot patients most likely to worsen so they can tailor monitoring and treatments sooner.
How similar studies have gone: Previous large observational ARDS cohorts have successfully identified prognostic factors and informed clinical practices, though local real-world data from this center may add region-specific insights.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with underlying diseases associated with high risk of ARDS, including but not limited to: sepsis, pneumonia, multiple trauma, pulmonary contusion, inhalation injury, massive blood transfusion, other high-risk conditions, or other factors causing excessive respiratory drive. * Patients meeting the inclusion criteria for a high-risk ARDS population. * Patients (or legal representatives) who have provided a signed and dated informed consent form. Exclusion Criteria: * Age under 18 years. * HIV infection. * Known immunodeficiency disorders (e.g., leukemia, common variable immunodeficiency, etc.). * History of solid organ or bone marrow transplantation. * Receiving treatment with G-CSF or GM-CSF. * Patients with a decision to withdraw from active treatment.
Where it's running
-
Fudan University, Zhong Shan Hospital
Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: Yuxian Wang, Doctor
- Email: wang.yuxian@zs-hospital.sh.cn
- Phone: 86-13482359545
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Pulse Wave vs Saline Bolus EIT to measure lung perfusion in ARDS
This study tests whether pulse wave EIT or saline bolus EIT can best show lung blood flow in ARDS patients on mechanical ventilation.
-
Biorepository and endotyping study for ARDS patients
This observational study tests whether creating a centralized ARDS biorepository and data set can help develop endotype and treatment-prediction tools for adults with ARDS.
-
BAL balance: ARDS through lung lavage and imaging to find different ARDS types
This study tests how bronchoalveolar lavage fluid and chest CT imaging can reveal different ARDS subtypes in adults with ARDS or severe pneumonia in the ICU.
-
Titrating PEEP in ARDS: Manual chest compression vs. electrical impedance tomography
In adults with ARDS on mechanical ventilation, the study tests whether a simple manual chest compression method can set the right PEEP as well as electrical impedance tomography (EIT).
-
Individualized PEEP Titration in ARDS Based on Lung Recruitment Potential
This pilot study tests two personalized PEEP strategies in adults with ARDS to see which approach better supports breathing mechanics by using a recruitment potential measure.
-
Single-dose inhaled rh-KGF-2 for ARDS in adults
This trial tests whether a single inhaled dose of rh-KGF-2 helps adults with ARDS who are on ventilators, using three dose levels to see which is safest and potentially most effective.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.